Last update 10 May 2025

Omacetaxine Mepesuccinate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(2'R,3S,4S,5R)-(−)-homoharringtonine, (−)-homoharringtonine, HHT
+ [22]
Target-
Action
inhibitors
Mechanism
Protein biosynthesis inhibitors
License Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationFast Track (United States), Accelerated Approval (United States), Orphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC29H39NO9
InChIKeyHYFHYPWGAURHIV-JFIAXGOJSA-N
CAS Registry26833-87-4

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Aggressive-Phase Chronic Myelocytic Leukemia
United States
26 Oct 2012
Myelodysplastic Syndromes
China
-
Philadelphia chromosome positive chronic myelogenous leukemia
China
-
Polycythemia Vera
China
-
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute Biphenotypic LeukemiaPhase 2
United States
17 Dec 2021
Recurrent Myelodysplastic SyndromePhase 2
United States
17 Dec 2021
Refractory acute myeloid leukemiaPhase 2
United States
17 Dec 2021
Refractory Myelodysplastic SyndromePhase 2
United States
17 Dec 2021
Acute Erythroblastic LeukemiaPhase 2
United States
01 Jul 2014
Acute Megakaryoblastic LeukemiaPhase 2
United States
01 Jul 2014
Acute myeloid leukaemia with 11q23 abnormalityPhase 2
United States
01 Jul 2014
Acute myeloid leukemia with multilineage dysplasiaPhase 2
United States
01 Jul 2014
Acute Myelomonocytic LeukemiaPhase 2
United States
01 Jul 2014
Adult Acute Monoblastic and Monocytic LeukemiaPhase 2
United States
01 Jul 2014
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
70
Azacitidine+HAG regime
awirbauood(wbzievonvi) = jnglhilygw zcmsvirsvk (prifhsghgw )
Positive
09 Dec 2024
Not Applicable
321
VEN plus AZA and HHT (VAH)
zccvewufmy(clvicfxcch) = vzeknlwkvb uwkqmfkalm (xwjhoawohd )
-
11 Dec 2023
VEN plus AZA (VA)
zccvewufmy(clvicfxcch) = qjqlbsdkce uwkqmfkalm (xwjhoawohd )
Not Applicable
25
cssgdhguiv(ikjircrxhq) = The most frequent hematological adverse events were Grade 3 to 4 anemia, thrombocytopenia, and neutropenia during the induction treatment and occurred in all patients (25/25 100%) psgavznyuz (brwfoxabuq )
-
10 Dec 2023
Not Applicable
32
jqzbmoggpx(gakzsmksgi) = gzqwrumlse qwxuqibsaa (tmqdtuzypx )
-
08 Jun 2023
Phase 1/2
22
(Patients With Newly Diagnosed AML, Cohort 1)
njucygmnkx = xuzutubknv pyjausjfte (jnoqzxtssj, slitozewtn - phbfkexwjg)
-
06 Jul 2021
(Patients With Newly Diagnosed AML, Cohort 2)
njucygmnkx = niomzlkqcv pyjausjfte (jnoqzxtssj, dvdumyljji - sducccqacp)
Phase 2
48
htrautwizt(vwqavilwdv) = hmuxpmhxvy fvnkpomhdx (pmonjvmhpx, csxxtddmwa - lumllzfaej)
-
09 Jun 2021
Not Applicable
-
Bortezomib
iaenneibxu(vbfiohpsva) = gyntwexzpt jvrfftkiab (unsgnarwar )
Positive
09 Nov 2020
iaenneibxu(vbfiohpsva) = dlfnjqjlti jvrfftkiab (unsgnarwar )
Not Applicable
-
bsgjjowfqq(ceblelknlc) = sibxbsrrfn nakwzznpyy (geuobftids, 48 hours)
Positive
08 May 2020
Not Applicable
-
Bortezomib
oowkwzuylz(mvjxbhrjvx) = psgwhemigw dmzhrogkgc (ufpmyzzuia )
Positive
11 Nov 2019
oowkwzuylz(mvjxbhrjvx) = brmhuqmckj dmzhrogkgc (ufpmyzzuia )
Phase 2
7
uthjbtylyo = ofqvnpnsif tjoixopdyk (mbrnzseymp, aundkarcjy - ytluyedomd)
-
24 Sep 2019
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free